Table 1.
Clinicopathologic data for all patients with gastric cancer (n = 30)
| Patients | sCD26 levels (pg/mL) | p value | |
|---|---|---|---|
| Tumor location n (%) | |||
| Upper | 6 (20 %) | 556.1 ± 77.2 | 0.986 |
| Middle | 11 (36.6 %) | 558.0 ± 133.8 | |
| Lower | 13 (43.4 %) | 564.2 ± 108.5 | |
| Tumor size n (%) | |||
| <3 cm | 15 (50 %) | 569.1 ± 101.2 | 0.800 |
| >3 cm | 15 (50 %) | 558.5 ± 121.6 | |
| Lauren’s Type n (%) | |||
| Intestinal | 20 (60 %) | 564.8 ± 94.8 | 0.934 |
| Diffuse | 10 (40 %) | 651.0 ± 145.9 | |
| Differentation n (%) | |||
| well | 4 (13.3 %) | 556.3 ± 95.4 | 0.681 |
| moderately | 20 (66.7 %) | 553.9 ± 120.0 | |
| poorly | 6 (20 %) | 559.8 ± 107.2 | |
| Tumor status n (%) | |||
| T1a | 0 | - | 0.781 |
| T1b | 2 (6.6 %) | 556.3 ± 0 | |
| T2 | 6 (20 %) | 563.4 ± 88.1 | |
| T3 | 12 (40 %) | 543.5 ± 146.9 | |
| T4a | 7 (23.3 %) | 636.7 ± 0 | |
| T4b | 3 (10 %) | 579.6 ± 88.9 | |
| Lymph node metastasis n (%) | |||
| N0 | 12 (40 %) | 602.8 ± 120.1 | 0.113 |
| N1 | 8 (40 %) | 511.3 ± 50.6 | |
| N2 | 4(6.6 %) | 447.7 ± 109.2 | |
| N3a | 2 (10 %) | 660.2 ± 0 | |
| N3b | 4 (3.4 %) | 636.7 ± 0 | |
| Metastatic disease n (%) | |||
| M0 | 26 (86.7 %) | 562.0 ± 114.7 | 0.660 |
| M1 | 4 (13.3 %) | 586.2 ± 83.5 | |
| Stage n (%) | |||
| Ia | 1 (3.4 %) | 546.1 ± 26.5 | 0.513 |
| Ib | 4 (13.3 %) | 587.2 ± 81.3 | |
| IIa | 2 (6.6 %) | 603.3 ± 144.3 | |
| IIb | 1 (3.4 %) | 626.8 ± 101.8 | |
| IIIa | 8 (26.6 %) | 587.1 ± 59.7 | |
| IIIb | 5 (16.7 %) | 613.8 ± 150.4 | |
| IIIc | 5 (16.7 %) | 564.8 ± 119.7 | |
| IV | 4 (13.3 %) | 518.9 ± 70.4 | |
| Resection type n (%) | |||
| R0 | 25 (83.3 %) | 562.0 ± 114.7 | 0.660 |
| R1-2 | 5 (16.7 %) | 586.2 ± 83.5 | |
| HER2 n (%) | |||
| positive | 15 (50 %) | 511.8 ± 84.8 | 0.006 |
| negative | 15 (50 %) | 619.1 ± 109.9 |